drugset / Trial / NCT02250885
KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the efficacy of Selinexor in patients with poorly differentiated lung and gastrointestinal and pancreatic neuroendocrine tumors.
Timeline
- Start
- 2014-08
- Primary completion
- 2016-08
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 50 mg/m2 | Oral |